Financial Information
This section of the Karyopharm Therapeutics InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing.
Please note: All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes. Karyopharm Therapeutics assumes no responsibility for the accuracy of this data and provides it for informational purposes only.
NASDAQKPTI
| Beta | (0.01) |
|---|---|
| Shares Outstanding | 114.4M |
| Average Volume (10 days) | 1.1M |
| Qtrly Dividend (Ann. Yield) | -- (--) |
Analyst Views
| Current Mean Recommendation | Buy |
|---|
| Strong Buy | 4 | |
|---|---|---|
| Buy | 1 | |
| Hold | 4 | |
| Underperform | 0 | |
| Sell | 0 |
Recent Insider Transactions
Bohlin Garen Director | 41,140 Buy Sep 12, 2023 |
|---|---|
Su Zhen | 68,000 Acquire Aug 31, 2023 |
Paulson Richard Ceo/President | (3,722) Sell Aug 7, 2023 |
Poulton Stuart EVP, Chief Development Officer | (2,845) Sell Jul 28, 2023 |
Cheng Sohanya Chief Commercial Officer | (1,839) Sell Jun 8, 2023 |